CSBR vs. MGTX, IMTX, CGEM, AUTL, MAZE, ALLO, PROK, CMPX, HUMA, and TECX
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include MeiraGTx (MGTX), Immatics (IMTX), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Maze Therapeutics (MAZE), Allogene Therapeutics (ALLO), ProKidney (PROK), Compass Therapeutics (CMPX), Humacyte (HUMA), and Tectonic Therapeutic (TECX). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology vs.
Champions Oncology (NASDAQ:CSBR) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
In the previous week, MeiraGTx had 1 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for MeiraGTx and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.04 beat MeiraGTx's score of 0.94 indicating that Champions Oncology is being referred to more favorably in the media.
Champions Oncology has a net margin of -1.12% compared to MeiraGTx's net margin of -633.05%. Champions Oncology's return on equity of 0.00% beat MeiraGTx's return on equity.
Champions Oncology has higher revenue and earnings than MeiraGTx. Champions Oncology is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Champions Oncology has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Champions Oncology currently has a consensus target price of $8.00, suggesting a potential downside of 21.42%. MeiraGTx has a consensus target price of $23.50, suggesting a potential upside of 251.80%. Given MeiraGTx's higher possible upside, analysts plainly believe MeiraGTx is more favorable than Champions Oncology.
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
MeiraGTx received 41 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 71.64% of users gave MeiraGTx an outperform vote while only 60.40% of users gave Champions Oncology an outperform vote.
Summary
MeiraGTx beats Champions Oncology on 9 of the 17 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CSBR) was last updated on 3/4/2025 by MarketBeat.com Staff
Free CSBR Stock Alerts